<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17708" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antiplatelet Medications</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Iqbal</surname>
            <given-names>Arshad Muhammad</given-names>
          </name>
          <aff>Oak Hill Hospital, Brooksville, FL</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lopez</surname>
            <given-names>Richard A.</given-names>
          </name>
          <aff>Geisinger Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hai</surname>
            <given-names>Ofek</given-names>
          </name>
          <aff>Nassau University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arshad Muhammad Iqbal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Richard Lopez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ofek Hai declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17708.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Over time, numerous antiplatelet agents have been developed with many indications. Antiplatelet medications divide into oral and parenteral agents, and oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet include clopidogrel, ticagrelor, and prasugrel, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban and eptifibatide are only available as parenteral agents and are used in acute phases of acute coronary syndrome. This activity reviews the indications, contraindications, actions, adverse events, and other key elements of antiplatelet drugs essential to clinical practice.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine&#x000a0;the mechanisms of action of the different antiplatelet agents.</p></list-item><list-item><p>Identify the appropriate indications for the various antiplatelet drugs.</p></list-item><list-item><p>Assess&#x000a0;the potential adverse event profiles of the different antiplatelet agents.</p></list-item><list-item><p>Communicate&#x000a0;interprofessional team strategies for improving care coordination and communication to enhance patient outcomes and minimize adverse events with antiplatelet medications.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17708&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17708">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17708.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Antiplatelet&#x000a0;medications are divided into oral and parenteral agents. Oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet agents include clopidogrel, ticagrelor, prasugrel, pentoxifylline, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban and eptifibatide are only available as parenteral agents and are used in acute coronary syndrome (ACS).<xref ref-type="bibr" rid="article-17708.r1">[1]</xref></p>
        <p>The following&#x000a0;is a list of indications of antiplatelet medications:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute coronary syndrome</p>
          </list-item>
          <list-item>
            <p>Post-percutaneous coronary intervention (PCI) with stenting</p>
          </list-item>
          <list-item>
            <p>Mechanical heart valves in combination with warfarin</p>
          </list-item>
          <list-item>
            <p>Acute ischemic stroke</p>
          </list-item>
          <list-item>
            <p>Post-percutaneous intervention of peripheral arterial disease</p>
          </list-item>
          <list-item>
            <p>Device closure of an atrial septal defect (ASD) for at least&#x000a0;6 months</p>
          </list-item>
          <list-item>
            <p>Stable angina</p>
          </list-item>
          <list-item>
            <p>Post-coronary&#x000a0;artery bypass grafting surgery</p>
          </list-item>
          <list-item>
            <p>Essential thrombocytosis</p>
          </list-item>
          <list-item>
            <p>Primary prevention of coronary artery disease</p>
          </list-item>
          <list-item>
            <p>Prevention of colon cancer</p>
          </list-item>
          <list-item>
            <p>Kawasaki disease</p>
          </list-item>
          <list-item>
            <p>Acute rheumatic disease</p>
          </list-item>
          <list-item>
            <p>Post patent ductus arteriosus (PDA) device closure for the first&#x000a0;6 months</p>
          </list-item>
          <list-item>
            <p>Acute pericarditis</p>
          </list-item>
          <list-item>
            <p>Atrial fibrillation with a high risk of stroke</p>
          </list-item>
          <list-item>
            <p>Primary prevention of venous thromboembolism</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17708.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Antiplatelets can be classified based on the mechanism of action as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Platelet aggregation inhibitors such as;
<list list-type="bullet"><list-item><p>Aspirin and related cyclooxygenase inhibitors</p></list-item><list-item><p>Oral&#x000a0;thienopyridines such as clopidogrel, ticagrelor, and prasugrel</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Glycoprotein platelet inhibitors (eg, abciximab, eptifibatide, tirofiban)</p>
          </list-item>
          <list-item>
            <p>Protease-activated receptor-1 antagonists (eg, vorapaxar)</p>
          </list-item>
          <list-item>
            <p>Miscellaneous (eg, dipyridamole - a nucleoside transport inhibitor and phosphodiesterase type 3 (PDE3) inhibitor,&#x000a0;cilostazol - also a PDE3 inhibitor)&#x000a0;<xref ref-type="bibr" rid="article-17708.r2">[2]</xref><xref ref-type="bibr" rid="article-17708.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Aspirin is the most commonly used oral antiplatelet drug. It irreversibly inhibits the cyclooxygenase enzyme (COX) activity in the prostaglandin synthesis pathway (PGH2). This prostaglandin is a precursor of thromboxane A2 (TXA2) and PGI2.&#x000a0;Thromboxane A2 works by inducing platelet aggregation and vasoconstriction, and COX-1 mediates its production, while PGI2 works by inhibiting platelet aggregation, induces vasodilation, and is mediated by COX-2. Low-dose&#x000a0;aspirin (75 mg&#x000a0;to 150 mg) can induce complete or near-complete inhibition of COX-1, thus inhibiting the production of TXA2, while larger doses are required to inhibit COX-2.<xref ref-type="bibr" rid="article-17708.r4">[4]</xref></p>
        <p>Oral thienopyridines&#x000a0;selectively inhibit adenosine diphosphate-induced (ADP-induced) platelet aggregation. These drugs are converted into active drugs with the help of the hepatic CYP450 system that can irreversibly inhibit the platelet P2Y12 receptor. Prasugrel is the most potent of all&#x000a0;3 drugs, has a rapid onset of action, and is superior to clopidogrel in patients undergoing coronary&#x000a0;stenting. Cangrelor&#x000a0;is a new intravenous, reversible P2Y12&#x000a0;receptor antagonist with a rapid onset of action. It achieves a significant degree of platelet inhibition compared with clopidogrel.<xref ref-type="bibr" rid="article-17708.r5">[5]</xref></p>
        <p>Glycoprotein platelet inhibitors work by inhibiting glycoprotein IIb/IIIa (GpIIb-IIIa) receptors on platelets, thus decreasing platelet aggregation. They are most commonly used in ACS.[3] These drugs are only available in an intravenous form and are, therefore,&#x000a0;used as short-term therapy.</p>
        <p>Dipyridamole has antiplatelet and vasodilating properties and inhibits&#x000a0;platelet cyclic nucleotide phosphodiesterase. This enzyme is responsible&#x000a0;for adenosine monophosphate (AMP) degradation to 5'AMP, which increases intra-platelet cyclic AMP accumulation and inhibits&#x000a0;platelet aggregation. It also blocks the uptake of adenosine by the platelets, increasing cyclic AMP.<xref ref-type="bibr" rid="article-17708.r6">[6]</xref></p>
        <p>Cilostazol is also reported to have vasodilatory, antiplatelet properties, and antiproliferative effects. It also reduces smooth muscle cell hyperproliferation and intimal hyperplasia after an injury to the endothelium.<xref ref-type="bibr" rid="article-17708.r7">[7]</xref></p>
      </sec>
      <sec id="article-17708.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Antiplatelet agent administration can&#x000a0;be via oral, rectal, or intravenous routes. Oral medications include aspirin, clopidogrel, ticagrelor, cilostazol, and dipyridamole. Intravenous drugs include GpII-IIIA inhibitors and can be used for a short period, most commonly during acute coronary syndromes before or during PCI. Aspirin is available as a rectal suppository if the patient cannot take the drug orally. The articles for each drug on the Statpearls platform cover individual agent dosing. The reader is advised to seek those articles out for specific dosing information.</p>
      </sec>
      <sec id="article-17708.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The following are the most common adverse effects associated&#x000a0;with antiplatelet medications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Aspirin-induced asthma</p>
          </list-item>
          <list-item>
            <p>Nasal polyps</p>
          </list-item>
          <list-item>
            <p>Upper gastrointestinal bleeding because of&#x000a0;chronic gastritis</p>
          </list-item>
          <list-item>
            <p>Ecchymosis</p>
          </list-item>
          <list-item>
            <p>Hematuria</p>
          </list-item>
          <list-item>
            <p>Epistaxis</p>
          </list-item>
          <list-item>
            <p>Ticagrelor-related dyspnea</p>
          </list-item>
          <list-item>
            <p>Hemorrhage</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia&#x000a0;<xref ref-type="bibr" rid="article-17708.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>Cilostazol's most common side effects are headache, nausea, diarrhea, pain, infection, upper respiratory symptoms, palpitations, arrhythmias, and peripheral edema.</p>
      </sec>
      <sec id="article-17708.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The most common&#x000a0;contraindications&#x000a0;for using antiplatelet agents are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Large esophageal varices</p>
          </list-item>
          <list-item>
            <p>Recent stroke within&#x000a0;2 years</p>
          </list-item>
          <list-item>
            <p>History of intracranial hemorrhage&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Significant thrombocytopenia&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Major surgery within 72 hours</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to the medication</p>
          </list-item>
          <list-item>
            <p>Acute clinically significant bleed</p>
          </list-item>
          <list-item>
            <p>End-stage renal disease on hemodialysis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Decompensated liver cirrhosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Severe hypertension with a BP over 200/110 mmHg</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure is a contraindication for the use of cilostazol&#x000a0;<xref ref-type="bibr" rid="article-17708.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17708.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before starting antiplatelet agents, the patient should undergo an assessment for bleeding risk. Advanced age, female gender, and impaired&#x000a0;renal function are&#x000a0;important&#x000a0;factors. The patient should know antiplatelet agents' risks, benefits, and alternatives. Monitoring is generally not required&#x000a0;for antiplatelet medications; however, if bleeding is present, bleeding time&#x000a0;is helpful to determine if a platelet transfusion is needed or if the medication requires discontinuation. In life-threatening&#x000a0;bleeding, such as massive upper gastrointestinal bleeding, the clinician should stop the drug as soon as possible. If the antiplatelet is an essential therapy, such as in post-coronary stenting&#x000a0;patients, the medications should be resumed as quickly as safely possible.</p>
        <p>The use of concomitant anticoagulants should be minimized as much as possible, as they increase the risk of bleeding by many times. Clopidogrel and ticagrelor should be discontinued for at least&#x000a0;5 days, and prasugrel should be discontinued for at least&#x000a0;7 days before major cardiac or non-cardiac surgery.</p>
      </sec>
      <sec id="article-17708.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Aspirin is the most commonly used of all antiplatelet drugs, so accidental intake is common.&#x000a0;The effect can be life-threatening if taken over 150 mg/kg of body weight. Supportive measures to decrease the absorption of the drug are achievable by using activated charcoal, but only if administered within 4 hours of ingestion. The patient needs monitoring for signs and symptoms of bleeding and the development of metabolic derangements, such as acidosis. If acidosis develops, immediate dialysis is indicated.<xref ref-type="bibr" rid="article-17708.r10">[10]</xref>&#x000a0;No antidote is available for most of these drugs; however, a monoclonal antibody against ticagrelor is in development, but it is not commercially available yet.</p>
      </sec>
      <sec id="article-17708.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Antiplatelet drug therapy requires an interprofessional team approach, including clinicians (MDs, DOs, NPs, PAs), specialty-trained nurses, and pharmacists. To achieve optimal patient results, these professionals must collaborate and engage in open communication.</p>
        <p>The choice of an antiplatelet agent depends on the clinical situation. Because of the availability of many antiplatelet agents, the ordering/prescribing clinician should consult with a cardiology or pharmacotherapy specialized pharmacist. When prescribing these agents, the pharmacist should review the patient's medication list and past diagnoses to determine if specific agents are recommended or contraindicated. Communication between the clinical provider and the pharmacists is essential to minimize adverse patient outcomes when using these drugs. A cardiac&#x000a0;pharmacist can offer direction regarding agent selection, drug-drug interactions, dose verification, and medication reconciliation for high-risk patients.</p>
        <p>The role of the cardiac nurse administering these medications in the acute setting involves monitoring for any acute adverse symptoms. Prompt communication by the astute nursing staff of an adverse reaction or a complication can significantly reduce patient morbidity and mortality.</p>
        <p>Nurses are often the first healthcare providers to verify these agents' therapeutic effectiveness and monitor for adverse effects. This role becomes crucial in patients receiving dual antiplatelet therapy, as is often the case for&#x000a0;preventing stent thrombosis or after an ACS event. The specialty-trained&#x000a0;clinicians&#x000a0;educate the patient on possible complications, the indications for the prescribed therapy, and the need for adherence to the medication treatment regimen. The nurse should communicate with the clinical provider and the pharmacist if noting any adverse reaction or if there is a concern for patient adherence to drug therapy so that alternative therapies can be considered. An interprofessional approach, with a multifaceted and targeted approach to treatment, is necessary to improve patient outcomes with antiplatelet medications.</p>
      </sec>
      <sec id="article-17708.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17708&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17708">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17708/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17708">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17708.s11">
        <title>References</title>
        <ref id="article-17708.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eikelboom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hirsh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Baglin</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e89S</fpage>
            <page-range>e89S-e119S</page-range>
            <pub-id pub-id-type="pmid">22315278</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kr&#x000f6;tz</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sohn</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Klauss</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Antiplatelet drugs in cardiological practice: established strategies and new developments.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2008</year>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>637</fpage>
            <page-range>637-45</page-range>
            <pub-id pub-id-type="pmid">18827913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hashemzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldsberry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Movahed</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review.</article-title>
            <source>Exp Clin Cardiol</source>
            <year>2008</year>
            <season>Winter</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>192</fpage>
            <page-range>192-7</page-range>
            <pub-id pub-id-type="pmid">19343166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warner</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Nylander</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whatling</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>72</volume>
            <issue>4</issue>
            <fpage>619</fpage>
            <page-range>619-33</page-range>
            <pub-id pub-id-type="pmid">21320154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubica</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kozinski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navarese</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Tantry</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kubica</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siller-Matula</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Fabiszak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Andruszkiewicz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gurbel</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Cangrelor: an emerging therapeutic option for patients with coronary artery disease.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2014</year>
            <month>May</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>813</fpage>
            <page-range>813-28</page-range>
            <pub-id pub-id-type="pmid">24393016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harker</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kadatz</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of dipyridamole.</article-title>
            <source>Thromb Res Suppl</source>
            <year>1983</year>
            <volume>4</volume>
            <fpage>39</fpage>
            <page-range>39-46</page-range>
            <pub-id pub-id-type="pmid">6356465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goto</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding.</article-title>
            <source>Atheroscler Suppl</source>
            <year>2005</year>
            <month>Dec</month>
            <day>15</day>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>3</fpage>
            <page-range>3-11</page-range>
            <pub-id pub-id-type="pmid">16275169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalyanasundaram</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lincoff</surname>
                <given-names>AM</given-names>
              </name>
              <collab>Medscape</collab>
            </person-group>
            <article-title>Managing adverse effects and drug-drug interactions of antiplatelet agents.</article-title>
            <source>Nat Rev Cardiol</source>
            <year>2011</year>
            <month>Sep</month>
            <day>13</day>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>592</fpage>
            <page-range>592-600</page-range>
            <pub-id pub-id-type="pmid">21912415</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnes</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Stanislawski</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bar&#x000f3;n</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maddox</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Nallamothu</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Rumsfeld</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.</article-title>
            <source>Circ Cardiovasc Qual Outcomes</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>406</fpage>
            <page-range>406-13</page-range>
            <pub-id pub-id-type="pmid">27245070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17708.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dargan</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose.</article-title>
            <source>Emerg Med J</source>
            <year>2002</year>
            <month>May</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>206</fpage>
            <page-range>206-9</page-range>
            <pub-id pub-id-type="pmid">11971828</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
